Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate
Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and cardiovascular disease treatments.
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced drug delivery technology.
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
Novo Nordisk Earnings Are Soon. It’s All About Weight-Loss Drug Sales.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. When Novo’s competitor Eli Lilly reported its earnings last week,
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.
New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity
Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in addition to weight loss. Read more here.
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.
pharmaphorum23h
Novo puts $285m into monthly GLP-1 based on Ascendis tech
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
BioPharma Dive1d
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...
Ascendis Pharma’s Strategic Partnership with Novo Nordisk: A Promising Buy Opportunity Fueled by TransCon Technology
Wells Fargo analyst Derek Archila maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of ...
BioSpace1d
Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...
FierceBiotech1d
Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
Ascendis Pharma’s Strategic Partnership with Novo Nordisk Signals Strong Buy Rating Amid Growing Obesity Market
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk ...
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 ...